helius medical technologies - HSDT

HSDT

Close Chg Chg %
3.13 -0.30 -9.42%

Closed Market

2.84

-0.30 (9.42%)

Volume: 373.41K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Company Overview: helius medical technologies - HSDT

HSDT Key Data

Open

$3.14

Day Range

2.79 - 3.21

52 Week Range

2.62 - 1,200.00

Market Cap

$140.01M

Shares Outstanding

41.30M

Public Float

23.74M

Beta

1.03

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1,283.76

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

523.51K

 

HSDT Performance

1 Week
 
-8.25%
 
1 Month
 
-15.88%
 
3 Months
 
-80.71%
 
1 Year
 
-99.42%
 
5 Years
 
-100.00%
 

HSDT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About helius medical technologies - HSDT

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

HSDT At a Glance

Solana Co.
642 Newtown Yardley Road
Newtown, Pennsylvania 18940
Phone 1-877-564-0008 Revenue 520.00K
Industry Medical Specialties Net Income -11,742,000.00
Sector Health Technology Employees 21
Fiscal Year-end 12 / 2025
View SEC Filings

HSDT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.493
Price to Book Ratio 2.36
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.054
Enterprise Value to Sales 1.424
Total Debt to Enterprise Value 0.016

HSDT Efficiency

Revenue/Employee 24,761.905
Income Per Employee -559,142.857
Receivables Turnover 0.819
Total Asset Turnover 0.093

HSDT Liquidity

Current Ratio 1.58
Quick Ratio 1.101
Cash Ratio 0.503

HSDT Profitability

Gross Margin -23.462
Operating Margin -2,665.962
Pretax Margin -2,258.077
Net Margin -2,258.077
Return on Assets -209.044
Return on Equity -688.882
Return on Total Capital -1,096.359
Return on Invested Capital -686.466

HSDT Capital Structure

Total Debt to Total Equity 1.133
Total Debt to Total Capital 1.12
Total Debt to Total Assets 0.339
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Helius Medical Technologies - HSDT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
522.00K 787.00K 644.00K 520.00K
Sales Growth
-21.03% +50.77% -18.17% -19.25%
Cost of Goods Sold (COGS) incl D&A
498.00K 644.00K 745.00K 642.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
374.00K 306.00K 162.00K 60.00K
Depreciation
174.00K 125.00K 45.00K 36.00K
Amortization of Intangibles
200.00K 181.00K 117.00K 24.00K
COGS Growth
-33.69% +29.32% +15.68% -13.83%
Gross Income
24.00K 143.00K (101.00K) (122.00K)
Gross Income Growth
+126.67% +495.83% -170.63% -20.79%
Gross Profit Margin
+4.60% +18.17% -15.68% -23.46%
2021 2022 2023 2024 5-year trend
SG&A Expense
18.15M 14.90M 12.17M 13.74M
Research & Development
5.99M 4.26M 2.94M 3.66M
Other SG&A
12.16M 10.64M 9.23M 10.08M
SGA Growth
+29.76% -17.89% -18.35% +12.93%
Other Operating Expense
- - - -
-
Unusual Expense
- (2.27M) (2.81M) (2.94M)
EBIT after Unusual Expense
(18.12M) (12.49M) (9.46M) (10.92M)
Non Operating Income/Expense
(8.00K) (1.58M) 612.00K (820.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(18.13M) (14.07M) (8.85M) (11.74M)
Pretax Income Growth
-28.32% +22.39% +37.11% -32.68%
Pretax Margin
-3,473.56% -1,788.06% -1,374.22% -2,258.08%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(18.13M) (14.07M) (8.85M) (11.74M)
Minority Interest Expense
- - - -
-
Net Income
(18.13M) (14.07M) (8.85M) (11.74M)
Net Income Growth
-28.32% +22.39% +37.11% -32.68%
Net Margin Growth
-3,473.56% -1,788.06% -1,374.22% -2,258.08%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(18.13M) (14.07M) (8.85M) (11.74M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(18.13M) (14.07M) (8.85M) (11.74M)
EPS (Basic)
-276764.6257 -39097.1251 -10918.92 -3249.8925
EPS (Basic) Growth
+37.44% +85.87% +72.07% +70.24%
Basic Shares Outstanding
65.51418650289999 359.9242391 810.5199979737 3.61K
EPS (Diluted)
-276764.6257 -39097.1251 -10918.92 -3249.8925
EPS (Diluted) Growth
+37.44% +85.87% +72.07% +70.24%
Diluted Shares Outstanding
65.51418650289999 359.9242391 810.5199979737 3.61K
EBITDA
(17.75M) (14.45M) (12.11M) (13.80M)
EBITDA Growth
-30.57% +18.57% +16.23% -14.01%
EBITDA Margin
-3,400.38% -1,836.47% -1,879.97% -2,654.42%

Snapshot

Average Recommendation HOLD Average Target Price 3,000.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -32.89 Median PE on CY Estimate N/A
Year Ago Earnings -3,250.00 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Helius Medical Technologies in the News